Lonza expands its HPAPI production capacity at its Switzerland facility after entering an agreement with AstraZeneca, and invests in manufacturing to establish efficiency.
San Diego, CA-based NanoComposix received its drug manufacturing license which it said will ensure clients are able to use one vendor throughout the product life cycle.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
Vetter’s German sites will be supplied with only CO2 neutral energy from renewable energy sources as the company continues to work towards greater sustainability.
Wasdell Group has acquired specialist manufacturer and packager, Honeywood Limited in an aim to build its manufacturing and packaging capacity in the UK to support European supply chain.
Recipharm is launching inhalation product solutions following its acquisition of Sanofi’s inhalation manufacturing business and increased use of inhaled drug products.
Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.
On the path to first-in-human clinical trials one of the main challenges is “velocity, ensuring rapid delivery of delivered drug product into the clinical program,” says CDMO.
Completion of early-stage development site expansion at the Illinois Science and Technology Park supplies Chicago-based drug companies with refrigeration services for complex APIs.
With 70% of its customers in North America and demand increasing, the UK-based CDMO Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina.
Small molecule manufacturing can result in product loss, as the materials manufactured come into contact with internal surfaces thereby impacting drying and creating disruptions in efficency and cost-effectivness.
Cure Pharma expands its DEA license to include authorization to manufacture both cannabis plant extracts and CBD within the scope of its patent portfolio.
Cambrex completes expansion of its R&D laboratory at its Milan site and adds a 12,000-liter reactor to its manufacturing facility during a $3m investment.
There is a common and often unchallenged perception that manufacturing quality standards in pharmerging countries are worrisome, but Lee Newton of Lonza argues this is not the reality.
ACG announces plans to grow its Latin American presence with its newest capsule production plant in Brazil, as it continues to expand its facilities in Asia-Pacific and Europe.
A drug is only as effective as its delivery system, and the advent of new molecules and new innovations have to be matched by enhanced delivery and containment methods, suggests West Pharma exec.
Haselmeier to provide assembly, labeling, and packaging services for its drug-device combination products following recent permission given to Germany-site.
US FDA issues draft guidance for its competitive generic therapies pathway, providing drugmakers with clarity on the designation and calling on the industry for more generic competition.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
Sharp invests $650,000 in its IRT solution to ensure proper supply allocations to support clinical trials and reduce costly overproduction for sponsors.
The US-based CDMO Cognate intends to collaborate with Astero to provide access to the latter’s cell thawing platform to improve product quality in clinical manufacturing and establish a center of innovation.
MedPharm expands its US Center of Excellence in Durham, North Carolina, in response to increasing demand for its topical and transdermal formulation development, and performance testing services.
Constantia Flexibles released its new packaging system, the Flexible Blister, which can be incorporated into existing production while offering a portable system for packaging.
Upperton Pharma’s new and expanded facilities received a positive inspection from MHRA, enabling both research and development and clinical manufacturing at the site.
Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.
Roquette has purchased a majority stake in excipient manufacturer Crest Cellose, in an aim to increase its footprint in India’s generic pharmaceutical market.
The UK Government has granted Arcinova funds to develop its digital manufacturing platform to produce patient-specific medicine at an accelerated rate.
The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.
The clinical-stage gene therapy company Voyager Therapeutics has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to expand its manufacturing capabilities.
Biovation expands its technology portfolio with all-encompassing tableting equipment to grow its production capacity and change specifications ‘on the fly’.
